Inhibikase Therapeutics (IKT)
(Delayed Data from NSDQ)
$1.35 USD
-0.12 (-8.16%)
Updated May 1, 2024 04:00 PM ET
After-Market: $1.35 0.00 (0.00%) 4:56 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 5/20/24 |
---|---|
Current Quarter | -0.79 |
EPS Last Quarter | -0.63 |
Last EPS Surprise | 19.23% |
ABR | 1.00 |
Earnings ESP
|
0.00% |
---|---|
Current Year | -1.71 |
Next Year | -1.52 |
EPS (TTM) | -3.56 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | NA | NA | NA | NA |
# of Estimates | NA | NA | NA | NA |
High Estimate | NA | NA | NA | NA |
Low Estimate | NA | NA | NA | NA |
Year ago Sales | 0.07M | 0.12M | 0.26M | NA |
Year over Year Growth Est. | NA | NA | NA | NA |
Earnings Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.79 | -0.37 | -1.71 | -1.52 |
# of Estimates | 1 | 1 | 1 | 1 |
Most Recent Consensus | -0.79 | -0.37 | -1.71 | -1.52 |
High Estimate | -0.79 | -0.37 | -1.71 | -1.52 |
Low Estimate | -0.79 | -0.37 | -1.71 | -1.52 |
Year ago EPS | -0.96 | -1.11 | -3.57 | -1.71 |
Year over Year Growth Est. | 17.71% | 66.67% | 52.10% | 11.11% |
Agreement - Estimate Revisions
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 0 | 0 |
Up Last 60 Days | 0 | 0 | 0 | 0 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 0 | 0 |
Down Last 60 Days | 0 | 0 | 0 | 0 |
Magnitude - Consensus Estimate Trend
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.79 | -0.37 | -1.71 | -1.52 |
7 Days Ago | -0.79 | -0.37 | -1.71 | -1.52 |
30 Days Ago | -0.79 | -0.37 | -1.71 | -1.52 |
60 Days Ago | -0.79 | -0.37 | -1.71 | -1.52 |
90 Days Ago | -0.79 | -0.37 | -1.71 | -1.52 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.79 | -0.37 | -1.71 | -1.52 |
Zacks Consensus Estimate | -0.79 | -0.37 | -1.71 | -1.52 |
Earnings ESP | 0.00% | 0.00% | 0.00% | 0.00% |
Surprise - Reported Earnings History
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Quarter Ending (3/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.63 | -0.86 | -1.11 | -0.96 | NA |
Estimate | -0.78 | -1.12 | -0.92 | -0.90 | NA |
Difference | 0.15 | 0.26 | -0.19 | -0.06 | 0.04 |
Surprise | 19.23% | 23.21% | -20.65% | -6.67% | 3.78% |
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more